NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.84 -0.52 (-0.62%) GOLD FUTURES
2,328.90 -13.20 (-0.56%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,615.04 -1,659.78 (-3.12%)
TheraVet SA (ALVET.PA)
- Business Wire
TheraVet reports Full-Year 2023 Financial Results and Provides the Preparatory Documents for the General Meeting of June 6th, 2024
GOSSELIES, Belgium, April 23, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces its Full-Year results for the year to December 31, 2023.
- Business Wire
TheraVet Reports 2023 Full Year and 2024 First Quarter Revenues
GOSSELIES, Belgium, April 10, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, reports its 2023 full year and 2024 first quarter revenues.
- Business Wire
TheraVet : BIOCERA-VET® is Now Available for the Management of Dental and Orthopedics Conditions in Horses
GOSSELIES, Wallonia, Belgium, March 13, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the launch of BIOCERA-VET® Equine in countries already covered by the Company.
